Harvard Drug $380 million facility includes $35 million revolver

By Sara Rosenberg

New York, Sept. 19 - Harvard Drug Group LLC's proposed $380 million credit facility (B+) will include a $35 million five-year revolver in addition to a $345 millions even-year term loan B, according to a market source.

Of the total term B amount, $45 million is available on a delayed-draw basis, the source said.

Morgan Stanley & Co. and Deutsche Bank Securities Inc. are the joint lead arrangers and bookrunners on the deal that will launch with a bank meeting on Thursday morning.

Proceeds will be used to refinance debt and finance the acquisition of the Rugby Group Inc. and another company.

Harvard Drug is a Livonia, Mich.-based independent pharmaceutical distributor.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.